Published in Pharmacotherapy on May 01, 2005
Duration of antimicrobial therapy in community acquired pneumonia: less is more. ScientificWorldJournal (2014) 0.78
Efficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia. Lung India (2012) 0.78
Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. Ther Clin Risk Manag (2007) 0.75
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog (2006) 3.58
Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol (2005) 3.47
Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol (2009) 3.20
A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell (2012) 2.56
Complementary adhesin function in C. albicans biofilm formation. Curr Biol (2008) 2.41
Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot Cell (2006) 2.21
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog (2012) 1.88
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother (2008) 1.70
Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis (2010) 1.68
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun (2010) 1.56
Portrait of Candida albicans adherence regulators. PLoS Pathog (2012) 1.51
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother (2010) 1.48
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Time course global gene expression analysis of an in vivo Candida biofilm. J Infect Dis (2009) 1.39
Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot Cell (2011) 1.35
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Regulation of iron transport in Streptococcus pneumoniae by RitR, an orphan response regulator. J Bacteriol (2004) 1.34
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis (2009) 1.32
Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother (2008) 1.28
Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J Clin Microbiol (2011) 1.18
Mechanisms of Candida biofilm drug resistance. Future Microbiol (2013) 1.13
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot Cell (2011) 1.07
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother (2013) 1.07
Comparative analysis of Candida biofilm quantitation assays. Med Mycol (2011) 1.07
Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob Agents Chemother (2008) 1.06
Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. Am J Respir Crit Care Med (2013) 1.05
Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother (2013) 1.03
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2012) 1.02
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother (2013) 0.98
Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules (2003) 0.96
Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans. PLoS One (2011) 0.95
Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother (2012) 0.92
Natural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylation. Org Lett (2012) 0.91
Regulatory role of glycerol in Candida albicans biofilm formation. MBio (2013) 0.90
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob Agents Chemother (2013) 0.89
Forazoline A: marine-derived polyketide with antifungal in vivo efficacy. Angew Chem Int Ed Engl (2014) 0.88
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother (2011) 0.86
The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis. Mol Microbiol (2013) 0.84
Synthesis and antibacterial activity of doxycycline neoglycosides. J Nat Prod (2013) 0.81
Heparin-binding motifs and biofilm formation by Candida albicans. J Infect Dis (2013) 0.81
Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis (2002) 0.81
Modeling of fungal biofilms using a rat central vein catheter. Methods Mol Biol (2012) 0.81
Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. Microbiol Spectr (2015) 0.81
Antifungal PK/PD considerations in fungal pulmonary infections. Semin Respir Crit Care Med (2011) 0.79
Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol (2011) 0.77
Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother (2013) 0.77
Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob Agents Chemother (2013) 0.75
Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris. J Nat Prod (2017) 0.75
Race and invasive fungal infection in solid organ transplant recipients. Ethn Dis (2014) 0.75